What stage does Syridex Bio invest at?

Syridex Bio invests at the Pre-Seed, Seed, Series A, Series B, Series C, Late Stage stages.

Where is Syridex Bio located?

Syridex Bio is headquartered in Princeton, US.

Syridex Bio

Impact investor

Princeton · Pre-Seed–Late Stage · 11 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Syridex Bio focuses on identifying emerging fields of science and medicine where innovation can drive transformative change in areas of unmet medical need. Combining market insight with a health-equity perspective, the firm prioritizes scientific, clinical, and digital opportunities that have the potential to meaningfully improve health outcomes across diverse patient populations.

Invests inBiotech Digital Health Healthtech Impact & Social Good Medical Devices Global Princeton United States

Source: firm website, verified Aug 3, 2026.

Stage

Pre-Seed–Late Stage

Princeton, New Jersey, US

Instruments

Equity

Founded

2022

Team · 11 people

from the firm's website & public directories

Squire Servance· Founder & Managing Partner

Founder and Managing Partner of Syridex Bio; formerly SVP, General Counsel & Corporate Secretary at Repligen and legal leader for Baxter International's global pharmaceuticals business. Holds a J.D. and MBA from Duke and a B.S. in biomedical engineering and cell biology/neuroscience from Rutgers.

s•••@syridexbio.comreveal

Veleka Peeples-Dyer· Partner

Life sciences executive with experience in FDA regulatory, legal, and global compliance, having served as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary, and as Chair of the North America Food and Drug Practice at Baker McKenzie. Holds a J.D. from University of South Carolina and a B.A. from Hampton University.

Joshua Adeoye· Principal

Physician-scientist and maxillofacial surgeon with public health experience serving as Principal at Syridex Bio. Previously Senior Associate at Adjuvant Capital; holds an MPH from Harvard and an MBA from Stanford.

Christopher Whitfield· Advisory Partner

Biopharma executive with 30+ years of leadership experience, most recently at Gilead Sciences as Regional General Manager of Africa focused on global health equity, and formerly CEO of Eli Lilly South Africa. Holds an MBA from Duke's Fuqua School of Business.

Anindya Roychowdhury

Former Partner and Head of Deal Advisory at KPMG with 30+ years of global transaction experience, now a Program Partner at The Hashgraph Association. Holds CGMA and CMA designations and an economics degree from Calcutta University.

Ben Duster

Founder and CEO of Cormorant IV Corporation, a consulting firm specializing in operational turnarounds and organizational transformations, and a 30-year Wall Street veteran. Holds an MBA from Harvard Business School and a J.D. from Harvard Law School.

Charles Corpening

Private equity investor with decades of Wall Street experience, most recently Senior Managing Director and Head of Investments at Ariel Alternatives. Graduate of Princeton with an MBA from Columbia Business School.

Kamil Ali-Jackson

Serial entrepreneur and attorney with 35+ years in life sciences who has co-founded multiple pharmaceutical and biopharmaceutical companies. Serves on two NASDAQ-listed biotech boards; holds a J.D. from Harvard Law and a B.A. from Princeton.

Owen May

Founder and CEO of May Davis Partners, an investment bank and advisory practice, with 30+ years of experience in M&A, corporate finance, IPOs, and turnarounds. Holds an MBA from Duke and a B.S. in biology from University of Miami.

Stephanie D. Taylor

Executive and subject matter expert in Health Economics and Outcomes Research and market access, currently driving portfolio optimization for J&J MedTech and formerly Executive Director at Eli Lilly. Holds a PhD in Pharmacy from Ohio State University.

Ted W. Love

Former President & CEO of Global Blood Therapeutics and current Chair of the BIO board, with senior R&D leadership roles at Onyx Pharmaceuticals, Nuvelo, and Genentech. Holds a B.A. from Haverford and an M.D. from Yale Medical School.

Frequently asked questions

What stage does Syridex Bio invest at?: Syridex Bio invests at the Pre-Seed, Seed, Series A, Series B, Series C, Late Stage stages.
What sectors does Syridex Bio focus on?: Syridex Bio focuses on Biotech, Digital Health, Healthtech, Impact & Social Good, Medical Devices.
Where is Syridex Bio located?: Syridex Bio is headquartered in Princeton, US.

Media · Podcasts & interviews

featuring the team

citybiz Interview: Squire Servance - Founder & Managing Partner at Syridex Bio

Citybiz Interviews · Squire Servance

Images

Similar investors

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

MaRS is a Toronto-based innovation hub and accelerator that supports Canadian startups from pre-seed funding through international expansion, offering workspace, mentorship, investor and customer connections, and sector-focused programming.

Gilde Healthcare

Gilde Healthcare is a specialist investment firm managing healthcare and climate-focused funds across venture & growth, and private equity strategies with a transatlantic team of sector specialists.

$1.1M – $55M

Portfolia

Portfolia operates thematic venture capital funds designed for women investors, backing companies in areas such as women's health, longevity, active aging, greentech, and fintech, while offering an educational and community-driven investing experience.